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ABSTRACT   
 
BACKGROUND: Drug resistance is a leading concern in control 
of TB. Resistance against rifampin as one of the most important 
drugs in the treatment of Mycobacterium tuberculosis is caused 
by mutations in the 81-base pair region of the rpoB gene encoding 
the β-subunit of RNA polymerase. This study aimed to characterize 
the mutations in the rpoB gene associated with rifampin resistance 
among M. tuberculosis. 
METHODS: This study was conducted on referred samples of 
patients who did not respond to anti-TB treatment, in Tuberculosis 
Regional Reference Laboratory at Shariati Hospital. Drug 
susceptibility of M. tuberculosis isolates was surveyed using a 
proportional method on LJ medium. The isolates with resistant to 
rifampin were reconfirmed and then the rpoB gene was amplified 
and sequenced.  
RESULTS: Among 27 resistant cases, 8, 11 and 8 people were from 
Iran, Afghanistan, and Turkmenistan, respectively. In 26 out of 27 
isolates, rpoB gene mutations were observed. The most prevalent 
mutations belonged to the codon 53. The most prevalent 
mutations belonged to the TCG (Ser) 531TTG (leu) with 
prevalence 51.8% (n=14), and GAC (Asp)516TAC (Tyr), CAC 
(His) 526GAC (Asp) and CAC (His) 526TAC(Tyr) mutations 
with prevalence 14.8%(n=4). Twenty-three isolates had just one 
mutation. 
CONCLUSION: The use of rpoB gene sequencing led to the lack 
of the need for growth of the organism in the culture medium, the 
direct use of clinical samples, reduction of biological risks and a 
detection about 96.3% of MDR TB cases lowering the cost of the 
treatment.  
KEYWORDS: Drug-resistant, Mycobacterium tuberculosis, rpoB 
gene, Rifampicin  
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INTRODUCTION 
 
TB infects one-third of the world's population, and 
nearly two million people die annually due to 
tuberculosis(1). Drug resistance is emerging 
globally, half a million new cases of MDR-TB 
(Multi-Drug-Resistance TB) were seen each year, 
and drug resistance is the main concern in control 
of TB. Since 1994, WHO reported the resistance 
to tuberculosis regularly. MDR and XDR-TB 
cause high mortality (more than 90%) in patients 
with HIV (2-4).  
Therefore, information collected of susceptibility 
to anti-TB drugs and surveillance and analysis of 
drug-resistant to TB in any region is useful in 
tracing of MDR and XDR-TB strains. Treatment 
of MDR is complicated and requires using toxic 
drugs with fewer side effects, and long duration of 
treatment can cause a serious reduction in the 
likelihood of successful treatment.  
Prompt treatment with anti-TB drugs and 
supportive therapy with corticosteroids reduces 
the rate of death and disability caused by TB, but 
this disease is still life-threatening and it is a major 
cause of death in some parts of the world (5). In 
2015, there were an estimated 10.4 million new 
TB cases over the world, of which 5.9 million 
(56%), 3.5 million (34%) and 1.0 million (10%) 
were among men, women, and children, 
respectively.  As well, it was reported 480 000 
new cases of multidrug-resistant TB (MDR-TB) 
and an additional 100 000 people with rifampicin-
resistant TB (RR-TB) who were also newly 
eligible for MDR-TB treatment(6). Rifampin 
resistance in M. tuberculosis usually occurs by a 
mutation in rpoB gene encoding the beta subunit 
of RNA polymerase. Although a single point 
mutation is sufficient to provide resistance to 
rifampin, many cases of rpoB multiple mutants in 
M. tuberculosis have been reported (6). Drug 
susceptibility testing (DST) using culture 
techniques of M. tuberculosis needs at least 7-10 
days, and sometimes takes 8-12 weeks for a final 
decision, and this time frame is inappropriate for 
management of patients and leads to an increase in 
MDR-TB strains. Hence, rapid, inexpensive and 
simple techniques for tracing the drug-resistant 
tuberculosis are required to screening patients at 
the high risk for MDR-TB. Of these techniques 
can be mentioned to the rapid molecular methods 
based on amplification of DNA (NAA) in order to 
follow the mutations in genes responsible for 
resistance to rifampin (rpoB), isoniazid (inhA, kat 
G) and ofloxacin (gyrA) (7).  In most studies 
conducted on rpoB gene, to investigate the 
mutations of resistance to rifampicin drug, many 
different mutations were seen in codon 81bp in 
diverse regions of the gene, but in a number of 
cases, have been reported without any mutation in 
this region. Such cases show that in addition to 
mutation, other mechanisms are involved in 
resistance to this drug. At the same time, it 
supports this concept that furthermore to the rpoB 
gene, one or more other genes also have 
contributed in resistance to the rifampin. It is 
possible that the occurrence of multiple mutations 
in different genes has a combined effect on 
resistance. Although various studies have been 
conducted in this field worldwide, no such study 
has ever been carried out in the northeast of Iran, 
and it is important to have information from all 
parts of the world. Therefore, this study aimed to 
characterize the mutations in the rpoB gene 
associated with rifampin resistance among M. 
tuberculosis isolated in Tuberculosis Regional 
Reference Laboratory in the northeast of Iran 
during 2015-2016. 
 
METHODS  
 
This cross-sectional study was conducted in 2015-
2016 on samples of patients referred to 
Tuberculosis Regional Reference Laboratory at 
Shariati Hospital in the Northeast of Iran. These 
patients did not respond to anti-TB treatment. M. 
tuberculosis strains were isolated and identified 
using Ziehl Neelsen staining; growth rate, colony 
morphology, pigment production, nitrate 
reduction, catalase, niacin tests and amplification 
of IS6110.  H37RV strain of M. tuberculosis was 
considered as control. Drug susceptibility testing 
for isolates was performed using a proportional 
method on the Lowenstein Jensen (LJ) medium. 
For reconfirmation of rifampin susceptibility 
pattern, samples were cultured on LJ medium 
containing a certain concentration of rifampin 
              
             Mutations of rpob Gene Associated with Rafampin…                               Tavanaee A. et al.                      
 
 
DOI:  http://dx.doi.org/10.4314/ejhs.v28i3.7 
 
301
antibiotic (susceptibility was determined at a 
concentration of 40 mg/ml for rifampin), and after 
incubation for 4-6 weeks in 37 ° C, the results 
were evaluated. In this method, when the colony 
growth in the medium containing antibiotic was 
equal or more than 1% of colonies numbers in the 
medium without antibiotic, it was considered as a 
rifampin-resistant strain. Isolates of M. 
tuberculosis which were resistant to rifampin were 
stored for further investigations. Patient 
demographic details such as age, gender, the onset 
of disease symptoms, duration of disease, duration 
of drug consumption and the treatment process 
were recorded by a physician for estimating any 
relationship with resistance. After confirming by 
phenotyping tests, genomic DNA was extracted by 
a CTAB protocol as described previously by van 
Soolingen and et al. (8). Briefly, 1.5 ml of the 
concentrated culture was heated at 80°C for 20 
min to kill the cells and centrifuged. Then the cells 
were resuspended in 500 ul of TE buffer (0.01 M 
Tris-HCl, 0.001 M EDTA [pH 8.0]). Lysozyme 
was added to a final concentration of 1 mg/ml, and 
the tube was incubated for 1 h at 37°C. Seventy 
microliters of 10% sodium dodecyl sulfate (SDS) 
and 6 ul of proteinase K (at a 10-mg/ml 
concentration) were added, and the mixture was 
incubated for 10 min at 65°C. An 80-pul volume 
of N-cetyl-N, N, N-trimethyl ammonium bromide 
was added. The cups were vortexed briefly and 
incubated for 10 min at 65°C. An equal volume of 
chloroform-isoamyl alcohol (24:1, vol/vol) was 
added, and the mixture was vortexed for 10 s. 
After centrifugation for 5 min, 0.6 volume of 
isopropanol was added to the supernatant to 
precipitate the DNA. After 30 min at -20°C and 
centrifugation for 15 min, the pellet was washed 
once with 70% ethanol, and the air-dried pellet 
was dissolved in 20 ul of 0.1 x TE buffer (0.001 M 
Tris-HCI, 0.0001 M EDTA [pH 8.0]). For 
amplification of genomic DNA, PCR technique 
was performed by designing primers for 
amplifying rpoB (RIF- R) gene; FP: 5-
TACGGTCGGCGAGCTGATCC -3, RP: 5- 
GGTTCATCGAAACGCCGTA -3. PCR reactions 
were performed using 1mM of MgCl2, 200 nmol 
of each primer, 100 mM of dNTPs, 1X PCR 
buffer and 10 ng of genomic DNA with 1 unit of 
Taq Hot Star DNA Polymerase Enzyme  
(Vivantis). The PCR program was as follows: 
denaturation at 94 C for 2 min, followed by 350 
cycles at 94 C for 30 s, 55 C  for 30 s and 72 C for 
30 s, and a final extension time of 7 min at 72 C. 
Then sequences were sent to South Korea, Bioneer 
Corporation, for sequencing using Sanger 
sequencing method. SPSS statistics software was 
used to perform statistical operations using chi-
square or non-parametric tests. 
 
RESULTS 
 
In this study, 55.6% (n=15) and 44.4% (n=12) of 
the patients were males and females, respectively. 
The mean age of patients was 45.59±9.04 years. 
The youngest and the oldest patients were 24 and 
57 years old, respectively. Among 27 positive 
cases, 8, 11 and 8 were from Iran, Afghanistan and 
Turkmenistan, respectively.  
In 26 samples out of 27, rpoB gene mutations 
were detected. In fact, the evaluation of gene 
mutations in 96.3% of the cases revealed MDR 
TB isolates.  The most prevalent mutations 
belonged to the TCG (Ser) 531TTG (leu) with 
prevalence 51.8% (n=14), and GAC 
(Asp)516TAC (Tyr), CAC (His) 526GAC (Asp) 
and CAC (His) 526TAC(Tyr) mutations with 
prevalence 14.8%(n=4) (Table1). 
On the other hand, 23, 2 and 1 patients had 1, 2 
and 3 mutations, respectively. However, one patient 
had no mutation. Ten patients had history of contact 
with TB patients, and 17 remaining cases did no 
show such history. Occupationwise, 33.3% (n=9) of 
the participants were housewife followed by workers 
(n=5) and farmers (n= 3).  As well as from each the-
job training, employee job and unemployed people, 
two patients were included. Of boutique, bakery, 
confectionary and mobile sailing jobs, one patient 
included in the current study. In 14 cases, 
transmission of tuberculosis occurred at home. In 4 
cases, its transmission occurred at the workplace, 
and one case in school. Finally, in 8 cases, the 
transmission route of tuberculosis was unknown.  In 
total, the mutation in codons; 531, 526, 516, 522 and 
533 were 55.5% (n=15), 33.3% (n=9), 14.8 % (n=4), 
3.7 % (n=1) and 3.7 % (n=1), respectively. The 
common sits of mutations highlighted with other 
colors and the color of primers was violet in Figure1. 
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Table 1: The pattern of rpoB gene mutations in patients with MDR-TB. 
 
 
type of Mutation  Numbers of patients Percentage (%) 
TCG(Ser)531TTG(Leu) 13 48.1 
GAC(Asp)516TAC(Tyr) 1 3.7 
CAC(His)526GAC(Asp) 2 7.4 
TCG(Ser)522CAG(Gln) 2 3.7 
CTG(Leu)533CCG(Pro) 1 3.7 
CAC(His)526TAC(Tyr) 4 14.8 
TCG(Ser)531CAG(Gln) 1 3.7 
GAC(Asp)516TAC(Tyr) 1 3.7 
CAC(His)526GAC(Asp) 0 0 
TCG(Ser)531TTG(Leu) 1 3.7 
GAC(Asp)516TAC(Tyr) 0 0 
CAC(His)526GAC(Asp) 0 0 
GAC(Asp)516TAC(Tyr) 1 3.7 
CAC(His)526AAC(Asp) 0 0 
No mutation 1 3.7 
 
CGTCGTCGACGCTGACCGAAGAAGACGTC
GTGGCCACCATCGAATATCTGGTCCGCTTG
CACGAGGGTCAGACCACGATGACCGTTCC
GGGCGGCGTCGAGGTGCCGGTGGAAACCG
ACGACATCGACCACTTCGGCAACCGCCGC
CTGCGTACGGTCGGCGAGCTGATCCAAAA
CCAGATCCGGGTCGGCATGTCGCGGATGG
AGCGGGTGGTCCGGGAGCGGATGACCACC
CAGGACGTGGAGGCGATCACACCGCAGAC
GTTGATCAACATCCGGCCGGTGGTCGCCG
CGATCAAGGAGTTCTTCGGCACCAGCCAG
CTGAGCCAATTCATGGACCAGAACAACCC
GCTGTCGGGGTTGACCCACAAGCGCCGAC
TGTCGGCGCTGGGGCCCGGCGGTCTGTCA
CGTGAGCGTGCCGGGCTGGAGGTCCGCGA
CGTGCACCCGTCGCACTACGGCCGGATGT
GCCCGATCGAAACCCCTGAGGGGCCCAAC
ATCGGTCTGATCGGCTCGCTGTCGGTGTAC
GCGCGGGTCAACCCGTTCGGGTTCATCGA
AACGCCGTACC 
 
Figure 1: The common sites of mutations have 
shown 
 
DISCUSSION 
 
Rifampin and isoniazid have the greatest anti-TB 
treatment potency and during the first 2 months of 
treatment can destroy more than 99% of tuberculosis 
bacilli. Therefore, the emergence of drug-resistant 
strains to either of these two antibiotics will bring 
further difficulties. Rifampin is considered as one of 
the most important anti-TB drugs, which by binding 
to beta-subunit of RNA polymerase, prevents from 
transcription initiation. Mutation in rpoB gene 
encoding the beta subunit of RNA polymerase 
enzyme can change the spatial form of the enzyme 
and leads to resistance to rifampin.  In recent years, 
several new techniques have been introduced to 
identify both the genotypic and phenotypic drug 
resistance. The advantages of genotypic methods are: 
shorter time-tested, no need to grow the organism in 
culture, the possibility of using clinical samples 
directly and less biological risk. However, all 
mechanisms are not known which lead to drug 
resistance (9). As mentioned in the results section, 
the average age of patients participating in the study 
was 45.59±9.04 years. Inconsistent with our results, 
in a study conducted by Ramirez and et al., in 2010 
(10), 154 resistant strains to rifampin were 
examined, the results showed the sensitivity and 
specificity of 91% and 98%, respectively. Also, 
resistance rate to Rifampin and INH was 87% and 
100%, respectively. The sensitivity and specificity 
for tracing of MDR-TB strains were reported 85% 
and 98%, respectively.  In another study carried out 
by GoEun Choi, et al in 2010, M. tuberculosis 
strains were collected in three groups. The results 
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were as follow: All strains except one case which 
was resistant to rifampin, alongside all susceptible 
strains to rifampin were identified correctly by 
analyzing HRMA and rpoB gene (11), that it is in 
line with our study. Also a study conducted by 
Malhotra et al., 2015; HRMA sensitivity and 
specificity in the detection of resistance to rifampicin 
were reported 90.3% and 97.4%, respectively (12). 
Due to the geographical location of Iran and its 
neighboring with countries with a high prevalence of 
TB and because of high immigration to Iran, this 
study aimed to investigate the efficacy and 
specificity of rpoB gene sequence, mutations, and 
polymorphisms of this gene for the detection of 
isolates resistant to rifampin. In our study, the most 
common mutations were observed in codon 531, 
526, 516, 533 and 522, respectively, which was in 
line with a study conducted by Silva et al., 2013; in 
which the most common mutation was reported in 
rpoB gene at codon 531 and 526 (9).  
In this study, the method of determining the 
resistance to rifampin was proportional in which the 
resistance level was not determined, and only 
resistant or susceptible modes were determined. All 
rpoB mutations cannot cause RMP resistance in all 
M. tuberculosis hosts, and the occurance mutations 
in some parts of the gene can cause mutation. In 
more than 95% of cases, the mutation occurs in one 
or more of these three mentioned sits. 
Overproduction of mutated rpoB cannot cause a high 
level of resistance to RMP, as mutation causes 
interruption of antibiotic binding. Consequently, the 
bacterium will resistant, and it does not affect the 
expression or production of the product. 
  In this study, 23 patients with 1 mutation, 2 
people with 2 mutations, 1 patient with 3 mutations, 
and in 1 case, no mutation was found. Similar results 
have been reported by global studies conducted in 
this field. In a study conducted by Bobadilla et al., in 
2001 on rifampin-resistant strains, they were not 
observed any mutations in the rpoB gene(13), which 
it is in line with  our results.  Also, in a study carried 
out by Ohno et al., 1996; among rifampin resistant-
strains of Mycobacterium tuberculosis, in one case, 
there was no mutation in the rpoB gene(14). In 
addition, a study conducted in India (Marin and et 
al., 2004) has found one isolate with no mutation. In 
our study, of 27 strains, 1 case had no mutation in 
the rpoB gene, which is in line with the above 
studies, and the mentioned strain was from Iran. 
Also, 1 out of rifampin-resistant M. tuberculosis 
strains with 3 mutations was from Iran. According to 
these results, it may be concluded that diversity and 
numbers of mutations in the codon of rpoB gene in 
rifampin-resistant M. tuberculosis in Iranian patients 
are more than neighboring countries such as 
Turkmenistan and Afghanistan.  The most mutations 
in Iranian race in 36.3% cases were observed at 
codon 531 and 526. Also mutation at codon 516 was 
observed in the 18.2% cases and 9.2% of cases had 
no mutation. Mutations at codon 531, 516, 526 were 
similar to Afghanistan race, and mutations in codon 
531 and 526 were similar to the Turkmenistan race. 
This difference might be due to the great migrations 
in recent years from neighboring countries with high 
prevalence of TB to Iran. In recent years, the 
marriage of Iranian with foreigners from some 
countries with high burden of tuberculosis has 
become more common, which leads to transmission 
of resistant strains of M. tuberculosis to Iran. In this 
study, the most common mutation was observed at 
TCG (Ser) 531TTG (leu) in 14 cases (51.8%). 
According to our results, a high prevalence of 
mutations in the rpoB gene confirms that its study is 
suitable for detection of rifampin resistance in M. 
tuberculosis isolated from Iranian clinical samples. 
These results also assist us in choosing different 
regions of a gene to study drug resistance that is 
more appropriate. The use of genotypic methods for 
detection of rifampin-resistant strains of MBT 
compared to phenotypic methods is affordable and 
useful because the results introduce in a shorter time. 
On the other hand, this method can be performed 
directly on samples and prevents from the side 
pollution, so it is recommended as a fast method to 
start treating the patients.  Rifampin-resistant strains  
are often associated with mutations at codon 531 of 
rpoB gene (9), in 36.3%, 58.4% and 57.2% of 
Iranian, Afghan and Turkoman races. This is 
particularly important in the use of new drugs to treat 
tuberculosis (15). Although heterogeneity in M. 
tuberculosis may obscure the results of molecular 
tests used for determining the antibiotic 
resistance(16), however, the obtained results are 
valuable. In the present study, the most common 
mutations were reported at codon 531, and other 
mutations were observed at codon 526, 516, 522 and 
533, respectively. Our results are inconsistent with 
many global studies. In Turkmen patients, mutation 
at codon 516 was not observed. The mutation in this 
               
   
                 Ethiop J Health Sci.                           Vol. 28, No. 3                     May 2018 
 
 
DOI:  http://dx.doi.org/10.4314/ejhs.v28i3.7 
 
304 
 
codon was only in Iranian and Afghan patients. It 
can be concluded that the first step in the evaluation 
of antimicrobial resistance to rifampin in Turkmen 
patients is not needed to check codon 516, and is 
better at first, be checked codon 531 and 526. With 
detection of the only codon, 531 can detect about 
63% of TB resistant strains to rifampin in the region. 
With detection of the codons 531 and 526 can 
identify approximately 72.6% of TB resistant strains 
to rifampin in Iranian patients.  
The use of rpoB gene sequencing led to the lack 
of the need for growth of the organism in the culture 
medium, the direct use of clinical samples, and 
reduction of biological risks. Detection nearby 
96.3% of MDR TB cases using this method lowering 
the cost of the treatment.  
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